泽璟制药：收到ATSA支付第一笔预付款5000万元

Core Viewpoint - Zejing Pharmaceutical has confirmed the receipt of a 50 million RMB upfront payment from Merck for exclusive market promotion services, which will be reported as non-current liabilities and amortized over the cooperation period [1] Group 1 - The company has received the first installment of 50 million RMB from ATSA as part of the agreement [1] - This payment is related to exclusive market promotion service authorization and will be treated according to accounting standards [1] - The amount will be reported as non-current liabilities after deducting value-added tax and will be amortized against sales expenses during the cooperation period [1]